JP2015509543A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509543A5
JP2015509543A5 JP2014561149A JP2014561149A JP2015509543A5 JP 2015509543 A5 JP2015509543 A5 JP 2015509543A5 JP 2014561149 A JP2014561149 A JP 2014561149A JP 2014561149 A JP2014561149 A JP 2014561149A JP 2015509543 A5 JP2015509543 A5 JP 2015509543A5
Authority
JP
Japan
Prior art keywords
hydroxy
amino
carbonyl
isoquinoline
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014561149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509543A (ja
JP6129217B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029912 external-priority patent/WO2013134660A1/en
Publication of JP2015509543A publication Critical patent/JP2015509543A/ja
Publication of JP2015509543A5 publication Critical patent/JP2015509543A5/ja
Application granted granted Critical
Publication of JP6129217B2 publication Critical patent/JP6129217B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014561149A 2012-03-09 2013-03-08 Hifヒドロキシラーゼインヒビターとしての4−ヒドロキシ−イソキノリン化合物 Expired - Fee Related JP6129217B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261609022P 2012-03-09 2012-03-09
US61/609,022 2012-03-09
PCT/US2013/029912 WO2013134660A1 (en) 2012-03-09 2013-03-08 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017047346A Division JP2017101089A (ja) 2012-03-09 2017-03-13 Hifヒドロキシラーゼインヒビターとしての4−ヒドロキシ−イソキノリン化合物

Publications (3)

Publication Number Publication Date
JP2015509543A JP2015509543A (ja) 2015-03-30
JP2015509543A5 true JP2015509543A5 (https=) 2016-04-28
JP6129217B2 JP6129217B2 (ja) 2017-05-17

Family

ID=48014301

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014561149A Expired - Fee Related JP6129217B2 (ja) 2012-03-09 2013-03-08 Hifヒドロキシラーゼインヒビターとしての4−ヒドロキシ−イソキノリン化合物
JP2017047346A Pending JP2017101089A (ja) 2012-03-09 2017-03-13 Hifヒドロキシラーゼインヒビターとしての4−ヒドロキシ−イソキノリン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017047346A Pending JP2017101089A (ja) 2012-03-09 2017-03-13 Hifヒドロキシラーゼインヒビターとしての4−ヒドロキシ−イソキノリン化合物

Country Status (10)

Country Link
US (1) US9409892B2 (https=)
EP (1) EP2834220B1 (https=)
JP (2) JP6129217B2 (https=)
CN (1) CN104470899B (https=)
AU (1) AU2013229922B2 (https=)
CA (1) CA2866556C (https=)
IL (1) IL234544A (https=)
NZ (1) NZ700760A (https=)
SG (1) SG11201405574UA (https=)
WO (1) WO2013134660A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
KR20210130849A (ko) 2012-07-16 2021-11-01 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
WO2015054579A1 (en) * 2013-10-11 2015-04-16 Isis Pharmaceuticals, Inc. Treatment of acute kidney injury with phd1 modulators
JP6506390B2 (ja) 2014-09-02 2019-04-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. キノリノン系化合物及びその薬物への使用
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
CN105367435A (zh) * 2015-12-03 2016-03-02 张伟 一种β-丙氨酸叔丁酯盐酸盐的制备方法
CN107188875B (zh) * 2016-03-15 2020-11-10 联化科技股份有限公司 一种取代苯酞类化合物的制备方法及其中间体
CN106478503A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 Roxadustat中间体的制备方法
EP3523279A1 (en) 2016-10-10 2019-08-14 Bristol-Myers Squibb Company Tricyclic sulfones as ror gamma modulators
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
CN110225753B (zh) 2017-01-28 2022-12-09 金凯(辽宁)生命科技股份有限公司 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法
TW201920108A (zh) * 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
CN108084090B (zh) * 2017-12-20 2020-03-17 北京六合宁远科技有限公司 一种药物中间体含氮杂环的溴代化合物的合成方法
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
WO2021073623A1 (zh) * 2019-10-18 2021-04-22 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN113754569B (zh) * 2020-06-04 2024-07-02 四川国为制药有限公司 一种中间体化合物及其制备方法和用途
WO2023072257A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
CN118414327A (zh) * 2021-12-17 2024-07-30 阿克比治疗有限公司 作为选择性phd1抑制剂的吡啶酰胺化合物、组合物和使用方法
EP4447963A1 (en) * 2021-12-17 2024-10-23 Akebia Therapeutics Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
US20250099455A1 (en) * 2022-01-13 2025-03-27 Fibrogen, Inc. Treatment for congestive heart failure
WO2024138317A1 (zh) * 2022-12-26 2024-07-04 中国科学院广州生物医药与健康研究院 一种甲状腺激素受体β激动剂化合物及其制备方法和应用
WO2024222890A1 (en) * 2023-04-28 2024-10-31 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof
KR20250174914A (ko) * 2023-04-28 2025-12-15 인실리코 메디신 아이피 리미티드 결정질 프롤릴 하이드록실라제 도메인 포함 단백질(phd) 억제제 및 이의 용도
EP4702028A1 (en) * 2023-04-28 2026-03-04 Insilico Medicine IP Limited Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof
CN117486797A (zh) * 2023-11-23 2024-02-02 传健生物医药(厦门)有限公司 一种罗沙司他关键中间体及罗沙司他的制备方法
WO2025252553A1 (en) 2024-06-04 2025-12-11 Syngenta Crop Protection Ag Pesticidally-active 2,2-dihalocyclopropyl compounds

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6716866B2 (en) 2001-06-13 2004-04-06 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
CN102552263A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2528232C (en) * 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
DE602005016800D1 (de) 2004-05-28 2009-11-05 Fibrogen Inc Hif-prolylhydroxylase-aktivitätstest
WO2006094292A2 (en) 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
EP2476669A1 (en) * 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
CN103497184A (zh) 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
BRPI0713350B1 (pt) * 2006-06-26 2022-04-12 Akebia Therapeutics Inc Composto, e, composição
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
SI2373172T1 (sl) 2008-12-03 2013-12-31 Presidio Pharmaceuticals, Inc. Inhibitorji HCV NS5A

Similar Documents

Publication Publication Date Title
JP2015509543A5 (https=)
US10968172B2 (en) USP30 inhibitors
NZ604831A (en) Apoptosis signal-regulating kinase inhibitors
CA2512582C (en) Antibacterial agents
NZ601655A (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
JP2007536224A5 (https=)
JP2015502335A5 (https=)
JP2013509376A5 (https=)
HRP20140105T1 (hr) Novi inhibitori seh i njihova upotreba
CA2536954A1 (en) C-kit modulators and methods of use
HRP20151260T1 (hr) Supstituirani nikotinamidi kao modulatori kcnq2/3
ZA200502755B (en) 1,3-Diamino-2-hydroxypropane prodrug derivatives.
WO2017195216A4 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
IL259975A (en) Pyridine compounds are converted to 4-phenyl as unsystematic trg5 agonists
US20070276011A1 (en) Plasminogen Activator Inhibitor-1 Inhibitor
NZ603198A (en) Novel hydroxamic acid derivative
JPWO2014098098A1 (ja) 複素環アミド誘導体及びそれを含有する医薬
SK94196A3 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them, manufacturing process thereof and their use
JP2015517981A5 (https=)
US20090306133A1 (en) New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087
CA2570942A1 (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicament
JP2004527503A5 (https=)
CA2645291A1 (en) Dibenzyl amine derivatives as cetp inhibitors
RU2014121394A (ru) Двузамещенные соединения диамино-3,4-циклобутен-3-диона-1,2, приемлемые для лечения паталогий, опосредованных хемокинами
JP2017507915A5 (https=)